ArticleTrials2022

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.

Nicholas A Turner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.